Cervical cancer is caused mainly by persistent HPV infection, which means prevention through vaccination is now a real possibility for future generations. For people already diagnosed, treatment depends heavily on how far the cancer has spread — and newer immune-based therapies are changing outcomes for advanced disease.
What's actually going on in research
Immune checkpoint inhibitors have moved into standard care for advanced cervical cancer, and trials are now testing them earlier in the treatment course, including before surgery. Antibody-drug conjugates targeting specific proteins on cervical cancer cells are showing strong results in heavily pretreated patients. Researchers are also refining radiation delivery techniques and testing whether less intensive treatment can preserve quality of life for early-stage disease.
Checkpoint inhibitors
Drugs that release the immune system's brakes — such as PD-1 and PD-L1 inhibitors — are now used earlier in treatment and being tested in combination with chemotherapy and radiation.
Antibody-drug conjugates
A new class of targeted drugs delivers chemotherapy directly into cervical cancer cells via a protein on the cell surface, sparing healthy tissue and showing benefit even after prior treatment failure.
HPV vaccination research
Trials are measuring how well vaccination programs in adolescents and young adults reduce cervical cancer rates over time, and testing catch-up vaccination strategies for older groups.
What to know before you search
Eligibility typically depends on disease stage, HPV and PD-L1 status, prior treatment history, and performance status.
What types of trials are currently open
- Treatment trials — Testing new drug combinations or immunotherapies in people with locally advanced or metastatic cervical cancer.
- Neoadjuvant trials — Testing treatments given before surgery or radiation to shrink tumors and improve outcomes.
- Prevention trials — Evaluating HPV vaccines and screening strategies to reduce cervical cancer incidence.
- Supportive care trials — Testing ways to manage side effects of radiation and chemotherapy, including sexual health and fertility preservation.
- Observational studies — Tracking long-term outcomes after treatment to understand survival, recurrence, and quality of life.
Recently added Cervical Cancer trials
Develop and Evaluate An Artificial Intelligence Assisted Prehabilitation Program for Returning to Work and Cost-effectiveness Analysis in Patients With Oral Cancer
The goal of this clinical trial is to develop and evaluate an Artificial Intelligence Assisted Prehabilitation Program (AI APP) for returning to work and cost-effectiveness analysis in patients with oral cancer (OC). The main questions it aims to answer are: * What kinds of needs are related to returning to work (RTW) in patients with OC from diagnosis to survival that we can incorporate into the development of AI APP to assist this population ? * How is the effect of the AI APP that based on findings from the first question for patients with OC on physical and psychological distress, fear of recurrence, self-efficacy in coping with cancer, communication, motor function, quality of life, and RTW? * How is the effect of the RTW AI prediction model to identify high-risk groups ? And how is the comprehensive cost effectiveness of benefits and quality of life of the AI APP for OC population? Researchers will compare patients without using AI APP to see if the AI APP works to assist with coping physical and psychological distress, communication, motor function, quality of life, and RTW issues for individuals with OC? Participants will: * Be asked to fulfill a structural questionnaire, or engage in a semi-structured one-by-one interview or a focus group to assess their physical, psychological, and social support needs in the first stage. * Be invited to participant the pilot testing of AI APP in the second stage. * Be provided and trained by 3-month AI APP for 3 months or cared as usual in the third stage. * Complete a structural questionnaire and follow up one year, including the baseline (before using the AI app) and at 1-2 weeks, 3 months, 6 months, 9 months, and 12 months after the baseline. * Engage in one-by-one interview or a focus group to assess user experiences of the AI APP.
Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
This is a prospective, randomized, phase II clinical study in patients with unresectable stage III-IVA esophageal squamous cell carcinoma (ESCC). Eligible patients will be randomly assigned in a 1:1 ratio to two treatment groups. The experimental group will receive 3 cycles of induction therapy with PD-1 antibody plus chemotherapy, followed by radiotherapy, and then maintenance therapy with PD-1 antibody monotherapy. The control group will receive concurrent chemoradiotherapy, followed by maintenance therapy with PD-1 antibody monotherapy. The primary endpoints are the complete response (CR) rate at 3 months after radiotherapy (assessed by investigators) and the 1-year progression-free survival (PFS) rate. Secondary endpoints include overall survival (OS), progression-free survival (PFS), duration of response, objective response rate (ORR), local-regional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), quality of life, and safety profile.
Find Cervical Cancer trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.